Stem cells targeted radioimmunotherapy of acute myelogenous leukemia with 211At-labeled anti-CXCR4 monoclonal antibody
Conclusions: Stem cells-targeted α-particle therapy with 211At-CXCR4 mAb is promising for AML , because absorbed dose delivered to target cells to normal organs would be high enough based on the dosimetry evaluation using tumor xenograft and sphere model. Acknowledgements: This study was financially supported by JSPS KAKENHI Grant Number JP16H05393.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Oriuchi, N., Aoki, M., Ukon, N., Washiyama, K., Shimoyama, S., Nishijima, K.-i., Takahashi, K., Ito, H., Ikezoe, T., Zhao, S. Tags: Basic Oncology & amp; Translational (Poster Session) Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Grants | Leukemia | Liver | Nuclear Medicine | Stem Cell Therapy | Stem Cells | Study | Thyroid | Thyroid Cancer | Urology & Nephrology